The 71 cent valuation is a 12 month price target
It applies to three indications only - gastric cancer, TNBC and NSCLC
The valuation does not include Vaxinia or OnCARlytics
In the Valuation summary from Roth Capital Partners was issued on 14th August 2022
"Our 12-month price target of AUD0.71 is based on a DCF analysis using a 15% discount rate that is applied to all cash flows and the terminal value, which is based on a 6x multiple of our projected FY2031 operating income of about AUD1.47 billion. We arrive at this valuation by projecting future revenue from CHECKvacc in TNBC, HER-Vaxx in advanced HER2+ gastric cancer, and PD1-Vaxx in NSCLC. Commercial success outside these financially modeled programs would serve as potential upside to our valuation."
.
Media Thread, page-6408
-
- There are more pages in this discussion • 9,812 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
-0.002(4.17%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.8¢ | 4.6¢ | $400.2K | 8.603M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 1876197 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 613421 | 6 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |